BioCryst Pharmaceuticals, Inc. (BCRX)
8.23
+0.11
(+1.35%)
USD |
NASDAQ |
Sep 14, 16:00
8.32
+0.09
(+1.09%)
After-Hours: 07:19
BioCryst Pharmaceuticals Price : 8.23 for Sept. 14, 2026
Price Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 14, 2026 | 8.17 | 8.38 | 8.095 | 8.23 | 5.097M |
| Sep 11, 2026 | 8.30 | 8.397 | 8.105 | 8.12 | 3.592M |
| Sep 10, 2026 | 8.34 | 8.46 | 8.045 | 8.29 | 9.001M |
| Sep 09, 2026 | 9.07 | 9.23 | 8.80 | 8.805 | 5.153M |
| Sep 08, 2026 | 9.122 | 9.40 | 8.96 | 9.065 | 9.688M |
| Sep 04, 2026 | 10.00 | 10.10 | 9.895 | 9.96 | 1.496M |
| Sep 03, 2026 | 10.15 | 10.22 | 9.935 | 10.09 | 1.974M |
| Sep 02, 2026 | 10.00 | 10.23 | 9.83 | 10.17 | 3.130M |
| Sep 01, 2026 | 9.72 | 9.955 | 9.63 | 9.92 | 3.367M |
| Aug 31, 2026 | 9.72 | 9.72 | 9.46 | 9.70 | 2.756M |
| Aug 28, 2026 | 9.822 | 9.96 | 9.72 | 9.82 | 2.703M |
| Aug 27, 2026 | 9.75 | 9.92 | 9.551 | 9.87 | 2.479M |
| Aug 26, 2026 | 9.77 | 9.90 | 9.71 | 9.83 | 1.859M |
| Aug 25, 2026 | 9.79 | 9.916 | 9.698 | 9.83 | 2.333M |
| Aug 24, 2026 | 9.50 | 9.755 | 9.48 | 9.68 | 2.010M |
| Aug 21, 2026 | 9.72 | 9.905 | 9.48 | 9.55 | 2.497M |
| Aug 20, 2026 | 9.92 | 9.988 | 9.595 | 9.66 | 2.329M |
| Aug 19, 2026 | 9.93 | 10.11 | 9.765 | 10.07 | 2.907M |
| Aug 18, 2026 | 9.89 | 9.94 | 9.545 | 9.70 | 2.122M |
| Aug 17, 2026 | 9.72 | 10.02 | 9.65 | 9.94 | 2.123M |
| Aug 14, 2026 | 9.68 | 9.800 | 9.46 | 9.74 | 3.821M |
| Aug 13, 2026 | 10.59 | 10.63 | 9.70 | 9.81 | 4.583M |
| Aug 12, 2026 | 10.33 | 10.68 | 10.10 | 10.59 | 3.866M |
| Aug 11, 2026 | 9.86 | 10.59 | 9.78 | 10.34 | 5.034M |
| Aug 10, 2026 | 9.33 | 9.855 | 9.280 | 9.84 | 4.017M |
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price Benchmarks
| Amgen, Inc. | 381.50 |
| Halozyme Therapeutics, Inc. | 107.94 |
| Neurocrine Biosciences, Inc. | 157.22 |
| Vertex Pharmaceuticals, Inc. | 519.51 |
| Agenus, Inc. | 7.13 |
Price Related Metrics
| PS Ratio | 2.070 |
| PEG Ratio | -0.0072 |
| Price to Free Cash Flow | 5.467 |
| Earnings Yield | -18.27% |
| Market Cap | 2.101B |
| PEGY Ratio | -0.0072 |
| Operating PE Ratio | 5.064 |
| Normalized PE Ratio | 14.74 |